Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.
Describes research to develop new compounds that match or exceed the pain relief provided by opioids while avoiding their shortcomings.
Describes research investigating a naturally occurring brain chemical that shows early promise as a treatment for addiction in animal studies.
April 2007 Describes research on a vaccine developed to facilitate smoking cessation by blocking nicotine penetration into the brain.
April 2007 Reports findings from a clinical trial investigating the effectiveness of naltrexone as a supplement to nicotine replacement therapy for smoking cessation.
February 2007 Discusses the work of NIDA’s Division of Basic Neuroscience and Behavioral Research, the Institute’s locus for studies into the fundamental brain mechanisms underlying drug abuse and addiction.